Phase I Trial of Palbociclib, a Selective Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Cetuximab in Patients with Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

OBJECTIVES: To test the safety of the CDK4/6 inhibitor palbociclib with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma(HNSCC). MATERIALS AND METHODS: A phase I trial using 3+3 design was performed to determine the dose limiting toxicity(DLT) and maximum tolerat...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oral Oncol
Main Authors: Michel, Loren, Ley, Jessica, Wildes, Tanya M., Schaffer, András, Robinson, Anthony, Chun, Se-Eun, Lee, Wooin, Lewis, James, Trinkaus, Kathryn, Adkins, Douglas
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5047057/
https://ncbi.nlm.nih.gov/pubmed/27311401
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.oraloncology.2016.05.011
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados